These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 10413388)

  • 1. Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies.
    Damiano AM; Patrick DL; Guzman GI; Gawel MJ; Gelinas DF; Natter HM; Ingalls KK
    Med Care; 1999 Jan; 37(1):15-26. PubMed ID: 10413388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.
    Lai EC; Felice KJ; Festoff BW; Gawel MJ; Gelinas DF; Kratz R; Murphy MF; Natter HM; Norris FH; Rudnicki SA
    Neurology; 1997 Dec; 49(6):1621-30. PubMed ID: 9409357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2007 Oct; (4):CD002064. PubMed ID: 17943766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group.
    McGuire D; Garrison L; Armon C; Barohn R; Bryan W; Miller R; Parry G; Petajan J; Ross M
    Neurology; 1996 May; 46(5):1442-4. PubMed ID: 8628496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the psychometric characteristics of the Macedonian version of the Oral Health Impact Profile questionnaire (OHIP-MAC49).
    Kenig N; Nikolovska J
    Oral Health Dent Manag; 2012 Mar; 11(1):29-38. PubMed ID: 22488030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALSFRS and appel ALS scores: discordance with disease progression.
    Voustianiouk A; Seidel G; Panchal J; Sivak M; Czaplinski A; Yen A; Appel SH; Lange DJ
    Muscle Nerve; 2008 May; 37(5):668-72. PubMed ID: 18288708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translation and Psychometric Evaluation of a Korean Version of the Amyotrophic Lateral Sclerosis-Specific Quality of Life - Revised.
    Oh J; Hong GS; Kim SH; Kim JA
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Feb; 18(1-2):92-98. PubMed ID: 27922756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. The Syntex-Synergen ALS/CNTF Study Group.
    McGuire D; Garrison L; Armon C; Barohn RJ; Bryan WW; Miller R; Parry GJ; Petajan JH; Ross MA
    J Neurol Sci; 1997 Oct; 152 Suppl 1():S18-22. PubMed ID: 9419049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options.
    Trail M; Nelson ND; Van JN; Appel SH; Lai EC
    J Neurol Sci; 2003 May; 209(1-2):79-85. PubMed ID: 12686407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
    Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in amyotrophic lateral sclerosis: determining a meaningful deterioration.
    Norquist JM; Fitzpatrick R; Jenkinson C
    Qual Life Res; 2004 Oct; 13(8):1409-14. PubMed ID: 15503836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of decline of functioning in persons with amyotrophic lateral sclerosis: responsiveness and possible applications of the Functional Independence Measure, Barthel Index, Rehabilitation Activities Profile and Frenchay Activities Index.
    De Groot IJ; Post MW; Van Heuveln T; Van Den Berg LH; Lindeman E
    Amyotroph Lateral Scler; 2006 Sep; 7(3):167-72. PubMed ID: 16963406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ).
    Alexander M; Berger W; Buchholz P; Walt J; Burk C; Lee J; Arbuckle R; Abetz L
    Health Qual Life Outcomes; 2005 Oct; 3():67. PubMed ID: 16259630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Participation restrictions in ambulatory amyotrophic lateral sclerosis patients: Physical and psychological factors.
    Van Groenestijn AC; Schröder CD; Kruitwagen-Van Reenen ET; Van Den Berg LH; Visser-Meily JMA
    Muscle Nerve; 2017 Nov; 56(5):912-918. PubMed ID: 28073181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS(ALSFRS-R) Japanese version].
    Ohashi Y; Tashiro K; Itoyama Y; Nakano I; Sobue G; Nakamura S; Sumino S; Yanagisawa N
    No To Shinkei; 2001 Apr; 53(4):346-55. PubMed ID: 11360474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictability of disease progression in amyotrophic lateral sclerosis.
    Czaplinski A; Yen AA; Simpson EP; Appel SH
    Muscle Nerve; 2006 Dec; 34(6):702-8. PubMed ID: 16967489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis.
    Neudert C; Wasner M; Borasio GD
    J Neurol Sci; 2001 Oct; 191(1-2):103-9. PubMed ID: 11676999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual quality of life is not correlated with health-related quality of life or physical function in patients with amyotrophic lateral sclerosis.
    Neudert C; Wasner M; Borasio GD
    J Palliat Med; 2004 Aug; 7(4):551-7. PubMed ID: 15353099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients' self-perceived burden, caregivers' burden and quality of life for amyotrophic lateral sclerosis patients: a cross-sectional study.
    Geng D; Ou R; Miao X; Zhao L; Wei Q; Chen X; Liang Y; Shang H; Yang R
    J Clin Nurs; 2017 Oct; 26(19-20):3188-3199. PubMed ID: 27874996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.